@article {Umeda1869, author = {Yukihiro Umeda and Yoshiki Demura and Miwa Morikawa and Masaki Anzai and Maiko Kadowaki and Shingo Ameshima and Tatsuro Tsuchida and Tetsuya Tsujikawa and Yasushi Kiyono and Hidehiko Okazawa and Takeshi Ishizaki and Tamotsu Ishizuka}, title = {Prognostic Value of Dual-Time-Point 18F-FDG PET for Idiopathic Pulmonary Fibrosis}, volume = {56}, number = {12}, pages = {1869--1875}, year = {2015}, doi = {10.2967/jnumed.115.163360}, publisher = {Society of Nuclear Medicine}, abstract = {The aim of this prospective study was to clarify whether dual-time-point 18F-FDG PET imaging results are useful to predict long-term survival of idiopathic pulmonary fibrosis (IPF) patients. Methods: Fifty IPF patients underwent 18F-FDG PET examinations at 2 time points: 60 min (early imaging) and 180 min (delayed imaging) after 18F-FDG injection. The standardized uptake value (SUV) at each point and retention index value (RI-SUV) calculated from those were evaluated, and then the results were compared with overall and progression-free survival. Results: A multivariate Cox proportional hazards model showed higher RI-SUV and higher extent of fibrosis score as independent predictors of shorter progression-free survival. The median progression-free survival for patients with negative RI-SUV was better than that for those with positive RI-SUV (27.9 vs. 13.3 mo, P = 0.0002). On the other hand, multivariate Cox analysis showed higher RI-SUV and lower forced vital capacity to be independent predictors of shorter overall survival. The 5-y survival rate for patients with negative RI-SUV was better than that for those with positive RI-SUV (76.8\% vs. 14.3\%, P = 0.00001). In addition, a univariate Cox model showed that positive RI-SUV as a binary variable was a significant indicator of mortality (hazard ratio, 7.31; 95\% confidence interval, 2.64{\textendash}20.3; P = 0.0001). Conclusion: Our results demonstrate that positive RI-SUV is strongly predictive of earlier deterioration of pulmonary function and higher mortality in patients with IPF.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/56/12/1869}, eprint = {https://jnm.snmjournals.org/content/56/12/1869.full.pdf}, journal = {Journal of Nuclear Medicine} }